FluoGuide is a clinical-stage biotech company, elevating precision surgery with FG001, illuminating cancer cells during surgery to enhance outcomes for patients
New - New exchange: Nasdaq First North
FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.
FluoGuide develops an imaging agent, applicable for maximizing surgical outcomes by making cancer fluorescent.
Successful application of FluoGuide’s products has the potential to lower system-wide healthcare costs because it will reduce the recurrence of cancer and lessen general surgical complications. Thereby, patients will require fewer readmissions to hospitals.
FluoGuide’s pipeline consists of product candidates that has the potential to light up 80% of solid cancers. We continue to advance our pipeline for the benefit of cancer patients, society, and our shareholders. FluoGuide’s lead product, FG001, is furthest along in clinical development for aggressive brain cancer, currently in phase II trials targeting patients undergoing surgical removal of high-grade glioma. Additionally, FG001 is in phase II clinical development for head and neck cancer as well as lung cancer.
27 November 2025
Investor Konference (in Danish)
27 November 2025
FluoGuide: Q3-Interview
